Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 134, Issue 2
July 11 2019
Issue Cover

Table of Contents

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS
Quest of biomarkers for venetoclax-treated CLL
Clinical Trials & Observations
Davide Rossi
View Articletitled, Quest of biomarkers for venetoclax-treated CLL
CLINICAL TRIALS AND OBSERVATIONS
Facing lenalidomide-refractory myeloma
Clinical Trials & Observations
Michele Cavo
View Articletitled, Facing lenalidomide-refractory myeloma
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Novel pathways of self- and cross-tolerance in monocytes
Sandra H. P. Farsky
View Articletitled, Novel pathways of self- and cross-tolerance in monocytes
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Calming the storm in HLH
Matt S. Zinter,Michelle L. Hermiston
View Articletitled, Calming the storm in HLH
Lymphoid Neoplasia
The Pandora’s box of thalidomide analogs and their substrates
Paola Neri
View Articletitled, The Pandora’s box of thalidomide analogs and their substrates
MYELOID NEOPLASIA
Deconstructing myelodysplastic syndromes
Monica del Rey Gonzalez,Christopher Y. Park
View Articletitled, Deconstructing myelodysplastic syndromes
MYELOID NEOPLASIA
Finding Neo (antigens, that is)
Johanna Olweus,Fridtjof Lund-Johansen
View Articletitled, Finding Neo (antigens, that is)

CLINICAL TRIALS AND OBSERVATIONS

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Clinical Trials & Observations
Andrew W. Roberts,Shuo Ma,Thomas J. Kipps,Steven E. Coutre,Matthew S. Davids,Barbara Eichhorst,Michael Hallek,John C. Byrd,Kathryn Humphrey,Lang Zhou,Brenda Chyla,Jacqueline Nielsen,Jalaja Potluri,Su Young Kim,Maria Verdugo,Stephan Stilgenbauer,William G. Wierda,John F. Seymour
View Articletitled, Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Supplemental data
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Clinical Trials & Observations
Joseph Mikhael,Paul Richardson,Saad Z. Usmani,Noopur Raje,William Bensinger,Chatchada Karanes,Frank Campana,Dheepak Kanagavel,Franck Dubin,Qianying Liu,Dorothée Semiond,Kenneth Anderson
View Articletitled, A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Signaling mechanisms inducing hyporesponsiveness of phagocytes during systemic inflammation
Nicole Freise,Alina Burghard,Theresa Ortkras,Niklas Daber,Achmet Imam Chasan,Saskia-L. Jauch,Olesja Fehler,Julia Hillebrand,Mosab Schakaki,Jessica Rojas,Bodo Grimbacher,Thomas Vogl,Andreas Hoffmeier,Sven Martens,Johannes Roth,Judith Austermann
View Articletitled, Signaling mechanisms inducing hyporesponsiveness of phagocytes during systemic inflammation
Supplemental data
Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis
Sabrin Albeituni,Katherine C. Verbist,Paige E. Tedrick,Heather Tillman,Jennifer Picarsic,Rachel Bassett,Kim E. Nichols
View Articletitled, Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis
Supplemental data

LYMPHOID NEOPLASIA

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
Adam S. Sperling,Michael Burgess,Hasmik Keshishian,Jessica A. Gasser,Shruti Bhatt,Max Jan,Mikołaj Słabicki,Rob S. Sellar,Emma C. Fink,Peter G. Miller,Brian J. Liddicoat,Quinlan L. Sievers,Rohan Sharma,Dylan N. Adams,Elyse A. Olesinski,Mariateresa Fulciniti,Namrata D. Udeshi,Eric Kuhn,Anthony Letai,Nikhil C. Munshi,Steven A. Carr,Benjamin L. Ebert
View Articletitled, Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
Supplemental data
A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening
Jing-Ping Zhang,Zhihui Song,Hong-Bo Wang,Lang Lang,Yuan-Zhong Yang,Wenming Xiao,Daniel E. Webster,Wei Wei,Stefan K. Barta,Marshall E. Kadin,Louis M. Staudt,Masao Nakagawa,Yibin Yang
View Articletitled, A novel model of controlling PD-L1 expression in ALK<sup>+</sup> anaplastic large cell lymphoma revealed by CRISPR screening
Supplemental data

MYELOID NEOPLASIA

Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes
Jasper Hsu,Andreea Reilly,Brian J. Hayes,Courtnee A. Clough,Eric Q. Konnick,Beverly Torok-Storb,Suleyman Gulsuner,David Wu,Pamela S. Becker,Siobán B. Keel,Janis L. Abkowitz,Sergei Doulatov
View Articletitled, Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes
Supplemental data
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms
Fiorella Schischlik,Roland Jäger,Felix Rosebrock,Eva Hug,Michael Schuster,Raimund Holly,Elisabeth Fuchs,Jelena D. Milosevic Feenstra,Edith Bogner,Bettina Gisslinger,Martin Schalling,Elisa Rumi,Daniela Pietra,Gottfried Fischer,Ingrid Faé,Loan Vulliard,Jörg Menche,Torsten Haferlach,Manja Meggendorfer,Anna Stengel,Christoph Bock,Mario Cazzola,Heinz Gisslinger,Robert Kralovics

There is a Blood Commentary on this article in this issue.

View Articletitled, Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms
Supplemental data

TRANSPLANTATION

Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure
Brief Report
Yi-Bin Chen,Nahel Elias,Eliot Heher,Jeannine S. McCune,Kerry Collier,Shuli Li,Candice Del Rio,Areej El-Jawahri,Winfred Williams,Nina Tolkoff-Rubin,Jay A. Fishman,Steven McAfee,Bimalangshu R. Dey,Zachariah DeFilipp,Paul V. O’Donnell,A. Benedict Cosimi,David Sachs,Tatsuo Kawai,Thomas R. Spitzer
View Articletitled, Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure

BLOOD WORK

Marked lymphocytosis and atypical cells with a cleft nucleus in a 1-month-old child
Jean-Baptiste Rieu,Francois Vergez
View Articletitled, Marked lymphocytosis and atypical cells with a cleft nucleus in a 1-month-old child
Unusual histiocytes in a pleural effusion: signature of a rare disease
Christelle El Khoury,Hussein Farhat
View Articletitled, Unusual histiocytes in a pleural effusion: signature of a rare disease

ERRATA

Table of contents. Blood. 2019;133(18):iii-iv.
View Articletitled, Table of contents. <em>Blood</em>. 2019;133(18):iii-iv.
Ward-Caviness CK, Huffman JE, Everett K, et al. DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis. Blood. 2018;132(17):1842-1850.
View Articletitled, Ward-Caviness CK, Huffman JE, Everett K, et al. DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis. <em>Blood</em>. 2018;132(17):1842-1850.
All Issues

Advertisement

Data mining for second malignancies after CAR-T
Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
MRD and EFS in pediatric T-lymphoblastic lymphoma
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement